Predictive analysis of breast cancer response to neoadjuvant chemotherapy through plasma metabolomics.
Miki YamadaHiromitsu JinnoSaki NaruseYuka IsonoYuka MaedaAyana SatoAkiko MatsumotoTatsuhiko IkedaMasahiro SugimotoPublished in: Breast cancer research and treatment (2024)
The application of plasma metabolomics, utilizing CE-MS and LC-MS, may serve as a tool for predicting the efficacy of neoadjuvant chemotherapy in breast cancer in the future after all necessary validations have been completed.